Florida Cancer Specialists & Research Institute Blood Cancer Research Showcased at Gathering of California Oncology Professionals

FORT MYERS, Fla., March 21, 2025 /PRNewswire/ -- A research study co-authored by Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders will be featured in an encore presentation at the MOASC 2025 Annual Oncology Summit & Research Symposium. FCS Director of Real-World Evidence Amanda Warner, MS, RN will present findings from the abstract, "Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment."

Additional co-authors of the study, published in the September 2024 issue of Clinical Lymphoma, Myeloma and Leukemia, include: FCS President & Managing Physician Lucio N. Gordan, MD, FCS medical oncologist Gustavo Fonseca, MD, FACP, FCS Senior Vice President & Data Officer Trevor Heritage, PhD and FCS Senior Director, Analytics Amy Ming, EDD, MBA, RN, PMP.

The study was initiated to describe the characteristics of patients with LR-MDS, a group of blood cancers where bone marrow does not function properly, treated with ESAs, an established treatment for MDS-related anemia using real-world data from FCS.

"These results demonstrate how real-word data gathered through our care of more than 350,000 patients annually is enriching the discovery, development and approval of new therapies," said Dr. Gordan. "Real-world evidence continues to enhance our robust clinical trials research that is transforming outcomes for patients with hematologic diseases and other cancers."

The FCS Real-World Evidence team provides unparalleled precision oncology insights and real-world evidence solutions. With a comprehensive, multifaceted approach, the team supports all study types—from preliminary consultation and study design to clinical endpoint review and the delivery of rich clinical datasets. Their collaborative methodology ensures the generation of high-quality, meaningful clinical insights that drive advancements in oncology research. To learn more, visit FCS Real-World Evidence.

MOASC is a state/regional affiliate of the Association of Clinical Oncology (ASCO) focused on ensuring the availability of optimal cancer care for residents of Southern California. The annual summit explores the latest advancements in oncology showcasing cutting-edge technologies, therapeutic agents, diagnostic tools and research platforms.

View the abstract: Clinical Lymphoma Myeloma and Leukemia

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-blood-cancer-research-showcased-at-gathering-of-california-oncology-professionals-302408016.html

SOURCE Florida Cancer Specialists & Research Institute